E29. Management of the menopause in breast cancer patients

European Journal of Cancer, Supplement

Volumn 2, Issue 9 SPEC. ISS., 2004, Pages 81-83

  Rozenberg, Serge ^a   Antoine, Caroline ^a   Vandromme, Jean ^a   Carly, Birgit ^a   Pastijn, Anne ^a   Neusy, Sarah ^a   Liebens, Fabienne ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CLONIDINE; GONADORELIN AGONIST; ISOFLAVONE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PHYTOESTROGEN; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TIBOLONE;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

EID: 9744239683     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.08.034     Document Type: Conference Paper

References (24)

1. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manag. 2002, Jun, 23(6), 501-509.
2. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991, Sep, 151(9), 1842-1847.
3. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS. For the Cache County Memory Study Investigators: hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women. The Cache County Study. JAMA 2002, 288, 2123-2129.
4. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 1994, Aug 17, 272(7), 540-545.
5. Natrajan PK, Gambrell Jr RD. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol. 2002, Aug 187(2), 289-294, Discussion 294-295.
6. Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause, 2003, Jul-Aug, 10(4), 277-285.
7. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer. 2002, Nov 1, 95(9), 1817-1826.
8. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol. 2000, Dec, 23(6), 541-545.
9. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001, Apr 15, 19(8), 2357-2363.
10. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. J Fam Practice. 2002, Dec, 51(12), 1056-1062.
11. Holmberg L, Anderson H. For the HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004, 363, 453-455.
12. Nikander E, Kilkkinen A, Mets-Heikkil M, Adlercreutz H, Pietinen P, Tiitinen A, Ylikorkala O. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003, 101(6), 1213-1220.
13. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002, May 1, 62(9), 2474-2477.
14. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000, May 16, 132(10), 788-793.
15. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000, Dec 16, 356(9247), 2059-2063.
16. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland Jr KM, Burnham NL. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994, Jan, 12(1), 155-158.
17. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer I 2003, Dec 3, 95(23), 1758-1764.
18. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland Jr KM, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997, Mar, 15(3), 969-973.
19. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996, Nov 6, 276(17), 1404-1408.
20. van der Klift M, de Laet CE, Coebergh JW, Hofman A, Pols HA. Bone mineral density and the risk of breast cancer: the Rotterdam Study. Bone. 2003, Mar, 32(3), 211-216.
21. Rozenberg S, Ham H, Liebens F. Screening mammography in elderly women. Research on Breast Cancer in Older Women Consortium. JAMA. 2000, Jun 28, 283(24), 3203.
22. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003, May 1, 21(9), 1660-1668.
23. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003, Dec, 30(6), 763-775.
24. Gambacciani M, Cappagli B, Piaggesi L, Ciaponi M, Genazzani AR. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcified Tissue Int. 1997, 61 Suppl 1:S15-S18.